Provenge FDA Approval History
FDA Approved: Yes (First approved April 29, 2010)
Brand name: Provenge
Generic name: sipuleucel-T
Dosage form: Suspension for Intravenous Infusion
Previous Name: APC8015
Company: Dendreon Corporation
Treatment for: Prostate Cancer
Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
Development timeline for Provenge
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.